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Abstract
Autism spectrum disorder (ASD) is a relatively common childhood onset neu-
rodevelopmental disorder with a complex genetic etiology. While progress has been
made in identifying the de novo mutational landscape of ASD, the genetic factors that
underpin the ASD's tendency to run in families are not well understood. In this study,
nine extended pedigrees each with three or more individuals with ASD, and others
with a lesser autism phenotype, were phenotyped and genotyped in an attempt to
identify heritable copy number variants (CNVs). Although these families have previ-
ously generated linkage signals, no rare CNV segregated with these signals in any
family. A small number of clinically relevant CNVs were identified. Only one CNV was
identified that segregated with ASD phenotype; namely, a duplication overlapping
DLGAP2 in three male offspring each with an ASD diagnosis. This gene encodes a
synaptic scaffolding protein, part of a group of proteins known to be pathologically
implicated in ASD. On the whole, however, the heritable nature of ASD in the families
studied remains poorly understood.
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1 | INTRODUCTION
Major progress in elucidating the genetic causes of the complex neu-
rodevelopmental disorder autism spectrum disorder (ASD) has been
made in recent years. ASD is one of the commonest early childhood
onset developmental disorders, occurring with a population prevalence
of more than 1% (Centers for Disease Control & Prevention, 2012). It is
characterized by core socio-communicative and behavioral symptoms,
and associated with major psychiatric and medical disorders (Anagnostou
et al., 2014). Variants of different allele frequencies are now known to
play an etiological role, with most progress having been made in the
identification of rare, often de novo, copy number variants (CNVs) and
single nucleotide variants (Woodbury-Smith & Scherer, 2018). As a result
of ascertainment and study design, many studies focus on only nuclear
families, including singletons, discordant sibpairs, and affected sibpairs,
and so the wider segregation of variants has not been studied. What is
particularly striking about ASD, however, is the fact that ASD tends to
segregate in families, with first and second-degree members of families
with ASD probands often diagnosed with ASD or classified with a lesser
variant termed the broader autism phenotype (BAP; Sasson et al., 2013).
Heritability estimates as high as 90% support a major role for genetic fac-
tors rather than common environment in explaining this familial nature
of ASD and BAP (Tick, Bolton, Happe, Rutter, & Rijsdijk, 2016). There is
also evidence that genetic predisposition may extend to other neuropsy-
chiatric disorders in families (De Rubeis & Buxbaum, 2015).
The fact that ASD often shows familial segregation has been investi-
gated in a series of genome-wide linkage studies (Abrahams &
Geschwind, 2008; Allen-Brady et al., 2010; Szatmari, 2007; Woodbury-
Smith et al., 2018). These have identified a number of genome-wide sig-
nificant signals for ASD and related phenotypes, earmarking genomic loci
that could potentially harbor ASD-associated variants. Some of these loci
overlap genes of potential significance to ASD, while other loci overlap
regions linked and/or associated with other neurodevelopmental disor-
ders. Only two loci, at 7q35 (Abrahams & Geschwind, 2008) and 20p13
(Werling, Lowe, Luo, Cantor, & Geschwind, 2014), have been replicated
at genome-wide significance.
More recent studies have also investigated the segregation of CNVs
across families (Woodbury-Smith et al., 2015). We reported previously
on the segregation of CNVs in 19 US and Canadian extended pedigrees
(Woodbury-Smith et al., 2015). Such families are likely to be enriched for
heritable forms of the disorder, and provide the opportunity to track vari-
ants more widely (Wijsman, 2012). Although we did not identify any rare
variants that were shared widely among family members with ASD
and/or BAP, there were examples of CNVs that segregated with ASD
phenotype in a subset of family members. None coincided with identified
linkage signals in these same families (Piven et al., 2013), pointing to a
potential source of complexity in ASD's heritable genetic architecture.
There is also evidence that CNVs of potential etiological significance may
segregate with other psychiatric disorders in such families (Sato
et al., 2012), consistent with the evidence of shared genetic risk, and
earmarking loci that cause brain vulnerability rather than disorder per se.
In this current study, we focused on an examination of CNVs in
nine newly recruited Canadian extended pedigrees. Having already
undertaken a genome-wide linkage study that included these same
families (Woodbury-Smith et al., 2018), we were interested in
whether any rare ASD and/or BAP segregating CNVs overlapped with
any of these identified linkage signals. Additionally, and based on our
previous study, we were also interested in identifying rare CNVs that
were shared among ASD/BAP family members.
2 | METHODS
2.1 | Recruitment
We recruited extended pedigrees with at least three ASD cases spread
across at least two nuclear families. All families were either known to the
authors through previous studies or identified through advertising. Initial
screening was by way of a telephone based assessment in conjunction
with the Autism Family History Interview (Piven et al., 1990). All families
who met the inclusion criteria were then followed for further clinical
assessment. To minimize etiologic heterogeneity, families were excluded
from the study if there was evidence of the following co-occurring medi-
cal conditions, thought to be etiologically related to autism, in one of the
index probands: tuberous sclerosis, neurofibromatosis, phenylketonuria,
Fragile X syndrome, or significant CNS injury, although no such families
were identified. All individuals were of northern European ancestry. Data
collection took place under Institutional Review Board's approval, and
the research was conducted in accordance with the World Medical Asso-
ciation Declaration of Helsinki. Written informed consent was obtained
from subjects or their proxy decision maker after the study had been
fully explained.
2.2 | Clinical diagnosis
ASD diagnosis was confirmed by expert clinical judgment incorporat-
ing information from the Autism Diagnostic Interview Revised (Lord,
Rutter, & Le Couteur, 1994) and Autism Diagnostic Observation
Schedule – Revised (Lord et al., 2000), which were administered by
trained and reliable clinicians. All participants classified as ASD met
DSM IV criteria for either Autistic Disorder, Asperger syndrome or
Pervasive Developmental Disorder Not Otherwise Specified
according to the criteria in Risi et al. (2006). Although DSM-IV criteria
were used at the time of assessment, all diagnosed participants also
meet the DSM 5 criteria for ASD.
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Among non-ASD family members, assessment for BAP was under-
taken. The BAP Questionnaire was used for diagnosis of BAP in individ-
uals greater than 15 years of age (Hurley, Losh, Parlier, Reznick, &
Piven, 2007). The measure was completed by the participant about
him/herself (the self-version) and by someone close to the participant
about him/her (parent or spouse, the informant version) to obtain an
average score (between the self and informant scores). Whenever avail-
able, the average scores were utilized. A BAP diagnosis was assigned if
an individual met gender-specific criteria in any domain.
Additional clinical evaluation was undertaken using the Wechsler
Abbreviated Scale of Intelligence (Pearson Clinical), the Vineland
Adaptive Behavior Scale (Pearson Clinical), the Repetitive Behavior
Scale (Lam & Aman, 2007), and the Oral and Written Language Scales
(Pearson Clinical). Clinical information pertaining to diagnosis of other
neurodevelopmental disorders, including epilepsy, along with known
neonatal complications was collected using a structured parent com-
pleted questionnaire.
2.3 | Genotyping
A total of 170 family members from the 9 extended pedigrees were gen-
otyped on one of four different platforms (a small number of individuals
were genotyped on more than one platform): Illumina HumanCoreExome
(N = 166), Illumina Omni2.5M or 1.0M (N = 18), Affymetrix Genome-
wide Human SNP array 6.0 (N = 15) or Affymetrix CytoScan HD
(N = 18). We called CNVs as previously described (Oskoui et al., 2015;
Pinto et al., 2011; Woodbury-Smith et al., 2015; Zarrei et al., 2018). Four
different CNV calling algorithms were used to annotate high-confidence
CNVs. These included Affymetrix Chromosome Analysis Suite (ChAS),
iPattern (Pinto et al., 2011), BioDiscovery Nexus (Darvishi, 2010), and
Partek Genomics Suite (Grayson & Aune, 2011). A stringent set of vari-
ants was defined for further analyses. For the Affymetrix chip, this set
included variants detected by one or both of ChAS or iPattern, and if
detected by only one of these, then also by one of Nexus or Partek. For
stringent calls on the X chromosome, we required calling by both ChAS
and iPattern. For Illumina generated genotypes, stringent calls included
variants detected by iPattern, and one of PennCNV (Wang et al., 2007)
or QuantiSNP (Colella et al., 2007). Stringent calls on the X chromosome
required calling by all three algorithms.
We analyzed CNVs covered by at least five consecutive probes and
those with a minimum length of 15 kb. CNVs were filtered to prioritize
rare variants that occurred with a frequency of <0.1% in control samples
(N = 10,851; refer to Zarrei et al., 2018, for list of control samples). For
the purpose of filtering, CNVs with >50% reciprocal overlap were
deemed identical. We also removed all CNVs that had >70% overlap
with a known segmental duplication. We further restricted our list to
those with more than 75% overlap with copy number stable regions,
according to the stringent CNV map of the human genome (Zarrei, Mac-
Donald, Merico, & Scherer, 2015). All clinically relevant CNVs described
in the index family have been validated using the SYBR green-based
quantitative PCR method, TaqMan Copy Number Assays and/or visuali-
zation of WGS generated bam files (see below) using the Integrated
Genomics Browser (IGV; Nicol, Helt, Blanchard, Raja, & Loraine, 2009).
The genomic coordinates presented in this article are based on the
February 2009 Human Genome Build (GRCh37/hg19).
2.4 | CNV prioritization
We first examined whether any of the rare CNVs overlapped linkage sig-
nals in these same families. Linkage signals were defined as those with a
PPL ≥ 0.1, whose margins were at PPL ≥ 0.05. We then prioritized dele-
tions and duplications ≥3 Mb in size. Next, variants were filtered to
extract only those that overlapped one or more coding exons, and then
the following CNVs were extracted: (a) variants overlapping a known
ASD gene (Yuen et al., 2017) and (b) variants congruent with known
genomic syndromes as those curated in DECIPHER (Firth et al., 2009) or
ClinGen (Rehm et al., 2015). Only those DECIPHER/ClinGen loci that
earmarked developmental brain syndromes were retained in our final list.
Further, variants were clinically classified as “likely benign,”, “of unknown
significance” (VOUS), and “likely pathogenic” according to the American
College of Medical Genetics guidelines (Kearney et al., 2011). CNVs in
cases with whole genome data from MSSNG project (Yuen et al., 2017)
were also visualized in IGV to further investigate structure of duplica-
tions and to refine breakpoints of variants.
2.5 | Whole genome sequencing
Twenty six individuals also underwent whole genome sequencing as
part of the MSSNG initiative (Yuen et al., 2017). Variant prioritizations
were followed as previously described (Yuen et al., 2017). Briefly,
identified variants were annotated, and likely deleterious mutations
prioritized to capture those that were rare (MAF ≤ 1%), LoF (non-
sense, splice site, frameshift), and damaging de novo missense muta-
tions (damaging as evidenced by four of following algorithms:
SIFT ≤ 0.05, Polyphen ≥ 0.95, CADD ≥ 15, Mutation Assessor scor-
e ≥ 2, PhyloP ≥ 2.4). MAF was based upon filtering according to
frequencies in the following control samples: 1000 Genomes Project
(Genomes Project Consortium et al., 2015), NHLBI-ESP
(Fu et al., 2013), ExAC (v.0.3.1) (Lek et al., 2016), and Complete Geno-
mics internal control data. Variants described in this article have been
validated by Sanger sequencing.
3 | RESULTS
A total of nine extended pedigrees were recruited. The total sample
includes 318 family members, among whom 170 were genotyped on
one or more platforms and 132 had phenotype data (122 with both
genotype and phenotype data). The sample comprised 46 individuals
diagnosed with ASD, 22 with BAP, and 68 with neither ASD nor BAP.
The clinical characteristics of these pedigrees are described in Supple-
mentary Table S1. Identified CNVs are detailed in Supplementary
Table S2.
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3.1 | CNVs segregating with linkage signals within
and across families
We first examined linkage signals generated by all nine pedigrees
combined. A number of CNVs overlapped these signals, but none
were inherited. As such, there were no segregating rare CNVs that
would theoretically explain any of the signals observed. The same was
true when examining pedigree specific linkage signals. Only two fami-
lies showed peaks above a 10% PPL threshold (Ped 4, ASD, X chromo-
some; Ped N1, BAP, chromosomes 9 and 20; Supplementary
Figure S1), but in neither case was there evidence of CNVs aligning
with these signals.
3.2 | Inherited CNVs segregating with ASD/BAP
phenotypes
A small number of rare CNVs overlapped known ASD genes and/or
recurrent known genomic syndromes (Table 1). One father of an ASD
male child, who himself met the criteria for BAP, had a 2.5 Mb clini-
cally pathogenic duplication at 22q11.21 (Wenger et al., 2016),
impacting many genes, several, including COMT and SLC25A1, impli-
cated in ASD and other neurodevelopmental disorders. The male off-
spring of this individual has a diagnosis of ASD and did not inherit this
mutation.
At five other loci, CNVs of unknown clinical significance were
identified. This included one duplication shared by an ASD male and
his unaffected female sibling impacting the ASD-implicated gene
NEDD9. This CNV tandemly duplicates three shorter isoforms of
NEDD9, but intragenic for the two larger isoforms of this gene. This
gene belongs to a family of molecules that mediate protein–protein
interactions in signal transduction pathways. This same ASD male also
had a tandem duplication that overlapped the cortical dysplasia impli-
cated gene TUBB2A, associated with complex cortical dysplasia and
other brain malformations (Romaniello et al., 2018). In Family
3 (Table 1), three members had a hemizygous deletion impacting the
ASD-implicated gene AGMO. One ASD female from this same family
had a large de novo, 1.6 Mb CNV duplication at Xp22.31, impacting
seven genes including STS.
The most striking finding was evidence of a paternally inherited
rare tandem duplication impacting the ASD-implicated gene DLGAP2
in three ASD-affected male offspring (Figure 1, individuals 003, 004,
and 006). This CNV partially duplicates DLGAP2 and ARHGEF10 and
fully impacts CLN8. None of the three male offspring is known to have
had neonatal complications or congenital abnormalities, and none has
ever had a seizure. For 003, 004, and 006 full-scale IQs are 108, 106,
and 96, and Vineland daily living skills are 117, 91, and 97, respec-
tively. These scores all lie in the average range (Table 2). Two of these
individuals, 004 and 006, are diagnosed with ADHD, and both have
impaired social functioning as indexed by their VABS social-domain
scores lying in the impaired range (i.e., <70, 004: social domain = 57,
006: social domain = 68). The third individual, 003, however, does not
have ADHD and his social functioning is 107, lying in the average T
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range. DLGAP2 is translated into a membrane bound protein that is
brain expressed and believed to play a role in synapse organization
and signaling in neuronal cells.
Individual 007, a male sibling with ASD from this same family has
a large 1.9 Mb de novo deletion on 16q23.3–24.1, impacting 27 genes,
several of which are ASD-implicated. His early development is notable
for motor floppiness, although the Vineland daily living skills domain is
consistent with level of functioning in the average range (93) and no
comorbidity is described. An IQ score is not available for this
individual.
Whole genome sequencing in this family revealed that four of the
five siblings also have a maternally inherited heterozygous nonsense
variant of MYO1A (chr 12: 57,441,459 G>A, p.R93X). The significance
of this is uncertain in light of its frequency in the population (0.28%,
https://gnomad.broadinstitute.org/variant/12-57441459-G-A). Two
of these siblings also harbor the DLGAP2 mutation, while the other
sibling has the 16q23.3–16q24.1 deletion (Figure 1; Table 2). These
four with the MYO1A variant individuals all have impairment in social
functioning as evidenced by their Vineland results. Of note, neither
the MYO1A nor the DLGAP2 mutations generated a linkage signal in
this family. No other clinically relevant was identified in these
individuals.
4 | DISCUSSION
Our examination of large, multigenerational pedigrees, each with at
least three members with ASD, has found no evidence of widely
segregating CNVs in these families. While a small number of CNVs
potentially implicated in ASD were identified, these did not explain
the heritable nature of the disorder in these families. Importantly,
these CNVs did not overlap any of the linkage signals previously iden-
tified in these families (Woodbury-Smith et al., 2018). As such, other
heritable genetic risk remains to be identified. Moreover, the exact
nature of how heritable risk and identified CNVs interact with each
other and additional factors needs to be more fully evaluated. The
possibility of an interaction between two or more genes in raising sus-
ceptibility to ASD has previously been argued, but such a mechanism
remains to be demonstrated.
One family with four male offspring all diagnosed with ASD was
characterized by the presence of shared mutations, none of which
neatly segregated with phenotype. One tandem duplication impacting
DLGAP2 was identified in three male offspring who inherited this
CNV from their father, who is of unknown phenotype. Two of the
three males with this CNV have been diagnosed with ADHD, and for
two social functioning as measured by the Vineland Adaptive Behav-
ior Schedule, is in the impaired range. This is a strong candidate for
ASD as DLGAP2 is strongly brain expressed (https://gtexportal.org/
home/gene/DLGAP2) and is identified as important in synapse devel-
opment (Rasmussen, Rasmussen, & Silahtaroglu, 2017). Indeed, as a
synaptic scaffolding protein, it interacts structurally at the domain
level with SHANK1-3 (Rasmussen et al., 2017; Takeuchi et al., 1997)
themselves implicated in ASD (Sato et al., 2012). Mouse models have
shown that knockout of DLGAP2 impacts social behavior, as well syn-
aptic structural integrity (Jiang-Xie et al., 2014). The potential role of
DLGAP2 in ASD is unclear, however, as one study failed to identify
F IGURE 1 Pedigree diagram for Ped 19 [Color figure can be viewed at wileyonlinelibrary.com]
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statistically significant difference in frequency of rare missense and
nonsense mutations in ASD cases versus controls, although the sam-
ple size was small: all cases were Asian, having been recruited in Tai-
wan (Chien et al., 2013). However, one other study has identified
ASD and other neurodevelopmental phenotypes in nine non-
overlapping families with DLGAP2 duplications (Poquet et al., 2017).
Four individuals with ASD in a single pedigree also had the same
stop-gain point mutation in MYO1A. Although IQ information was
unavailable for one individual, the other three all had intellectual abil-
ity in the average range. Despite this, however, their social functioning
was in the impaired to borderline impaired range. Of additional rele-
vance, the two offspring with ADHD both had DLGAP2 and MYO1A
mutations. However, other aspects of phenotype, including language
skills and medical history, did not clearly differentiate between indi-
viduals in this family with different mutations. The one individual with
both a MYO1A mutation and large 16q23.3–16q24.1 deletion was
floppy at birth but otherwise unremarkable in terms of perinatal com-
plications and medical history.
We have previously highlighted the complexity of making geno-
type phenotype correlations in ASD, particularly in view of the pheno-
typic heterogeneity and infrequency of individual mutations
(Woodbury-Smith et al., 2017). This is compounded by the variable
penetrance of these mutations. Although we are not able to confi-
dently make causal statements, overcoming this formidable obstacle
will require the accumulation of phenotype and genotype information
afforded by in-depth studies such as ours. Such variable penetrance is
widely recognized in ASD and other neurodevelopmental disorders
(Bateman et al., 2018; Le, Williams, Alaimo, & Elsea, 2019; Ropers &
Wienker, 2015), even at “high risk” neurodevelopmental loci. For
example, the well-described 2q37 deletion syndrome is associated
with a wide range of neurodevelopmental and medical phenotypes,
and it is only by considering size and position of CNV along with
downstream expression of underlying genes and their interacting part-
ners, that the relationship of genotype to phenotype is more fully
appreciated (Le et al., 2019). Moreover, similar to ours, other studies
have also found variable penetrance for identical mutations in family
members of identified probands (Bateman et al., 2018).
We did identify a number of other CNVs in ASD and/or BAP
cases that have been previously implicated in ASD (COMT,
SLC25A1, NEDD9, and AGMO) and cortical dysplasia (TUBB2A;
Yuen et al., 2017). The likely variable penetrance of these muta-
tions, however, is evidenced by their occurrence in both BAP cases
as well as typically developing siblings of ASD probands. Further
work, including functional studies, is therefore required to improve
our understanding of their penetrance in relation to ASD. Indeed, it
is notable that several of the identified CNVs are interpreted clini-
cally as of unknown significance. This level of uncertainty presents
major problems for genetic counselors tasked with explaining cau-
sality and risk to families. A further CNV impacting STS is associ-
ated with X-linked ichthyosis, itself described in association with
neurodevelopmental phenotypes including ASD and ADHD (Kent
et al., 2008).
TABLE 2 Phenotypes of Ped 19 (see Figure 1 for pedigree)
Patient ID 001 002 003 004 005 006 007
Sex F M M M M M M
ASD/BAP - - ASD ASD ASD ASD ASD
Genetics 355 kb dup
8p23.3
MYO1A p.
R93X +/−
355 kb dup 8p23.3;
MYO1A p.R93X +/−
355 kb dup
8p23.3
MYO1A p.
R93X +/−
355 kb dup 8p23.3;
MYO1A p.R93X +/−
1.9 Mb dn del
16q23.3–q24.1
IQ: FSIQ - - 108 106 104 96 -
PRI - - 112 108 101 99 -
VCI - - 103 102 105 94 -
Adaptive
behavior: SSS
- - 107 57 80 68 79
CSS - - 98 84 81 91 85
DSS - - 117 91 93 97 93
RBS: Total - - 43 51 22 56 17
SCQ - - 20 19 17 16
OWLS II - - 106 107 104 109
Epilepsy - - No No No No No
ADHD - - No Yes No Yes No
Congenital
abnormalities
- - No No No No No
Neonatal
complications
- - No No No No Hypotonia
Abbreviations: -, data unavailable; Adaptive behavior (Vineland) SSS, social scaled score; CSS, communication scaled score; DSS, daily living scaled score;
OWLS II, oral and written language scales; PRI, perceptual reasoning index; RBS, repetitive behavior score; SCQ, social communication questionnaire; VCI,
verbal comprehension index; (Wechsler) FSIQ, full-scale IQ.
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Extended pedigrees are a valuable resource for the identification
of heritable genetic causes of ASD. Many of the genetic variants iden-
tified so far as ASD implicated are de novo and therefore will not
explain ASD's heritability of ~90% (Tick et al., 2016). Families such as
the ones studied here often contain members with milder autism phe-
notypes, termed BAP. We have shown previously that these pedi-
grees can individually generate reasonable sized linkage signals, with
strong evidence that these signals are consistent with segregating
uncommon variants.
Moreover, such families offer the opportunity to tease out the
relative roles of environmental risk factors that may be shared among
affected members. While we do not expect variants to be shared
across different families, it is likely that within individual families some
shared variants will explain the propensity for clustering of ASD and
other mental disorders even in the presence of intrafamilial genetic
heterogeneity. Therefore, although the findings are modest, families
such as those studied here are a unique resource for future studies
tacking the complex genetic etiology of ASD.
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